Fibronectin Binding Protein Vaccine with Iscom Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Staphylococcus aureus (SA) infections, particularly mastitis in bovine species, are ineffective due to the bacterium's ability to hide antigens and manipulate the host immune system, leading to challenges in inducing a robust and long-lasting immune response.
Innovation Solution
A composition comprising fibronectin binding proteins or peptides with fibronectin binding domains, combined with an iscom matrix complex and/or liposomes, and saponins, which enhances immune responses by promoting both humoral and cellular immunity, thereby overcoming the immune evasion strategies of SA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines are used against Staphylococcus aureus, then the vaccine can be administered, but the immune response is weak and short-lasting due to bacterial immune evasion mechanisms
Solution Approach 1:
The patent combines fibronectin binding protein (antigen) with iscom matrix complex containing saponins and lipids to create a composite vaccine formulation. This composite structure enhances both the reliability and duration of immune response by integrating multiple functional components that work synergistically to overcome bacterial immune evasion mechanisms
Solution Approach 2:
The patent modifies the physical and chemical parameters of the vaccine formulation by using iscom matrix complex with specific saponin-lipid compositions. This changes the delivery characteristics and immunogenicity parameters of the antigen, resulting in improved immune response durability
2Reliability
If fibronectin binding protein is used as antigen, then the vaccine targets essential adhesion molecules, but the bacterium can still hide antigens and manipulate the immune system
Solution Approach 1:
The iscom matrix complex acts as an intermediary delivery system that enhances the presentation of fibronectin binding protein to the immune system. This intermediary structure overcomes the harmful immune evasion mechanisms by improving antigen visibility and immune system activation
Solution Approach 2:
The vaccine formulation changes the immunogenicity parameters by combining the antigen with iscom matrix, transforming a weakly immunogenic protein into a highly immunogenic composite that effectively counters bacterial immune manipulation strategies
3Reliability
If iscom matrix complex with saponins and lipids is used as adjuvant, then humoral and cellular immunity are enhanced, but the formulation complexity increases
Solution Approach 1:
The patent merges saponins and lipids into a unified iscom matrix complex structure, combining multiple adjuvant components into a single integrated formulation system that simplifies manufacturing while maintaining enhanced immune response capabilities
Data Source
AI summary
The present invention relates to a composition comprising at least one fibronectin binding protein, and/or at least one a truncated fibronectin binding protein and/or at least one fibronectin binding peptide, all comprising at least one fibronectin binding domain; and at least one Iscom matrix complex and/or liposome and/or at least one lipid and at least one saponin, whereby the at least one lipid and the at least one saponin may be in complex, solution or suspension. Further, it regards use thereof for the production of a vaccine against a micro organism that comprises at least one one fibronectin binding domain. It also regards a kit of parts comprising at least two compartments, wherein one compartment comprises at least one truncated fibronectin binding protein and/or a fibronectin binding peptide, that comprises at least one fibronectin binding domain, and another compartment comprises an instruction for use and/or an Iscom matrix complex and/or an iscom complex and or a liposome. Further it relates to a method for vaccination of an individual.